ANALYSTS ESTIMATE

Novo blames US health system after criticism over Wegovy price, Bloomberg reports

​The drugs belong to a class of treatments known as GLP-1s, which help regulate blood sugar and cause the stomach to empty more slowly. Analysts estimate the market for these drugs could be about $150 billion by the early 2030s as their use expands beyond obesity and diabetes and supply constraints ease.